DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV-Reference-Cited by-同舟云学术

DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV

Published:2019-05-13 Issue:7 Volume:13 Page:693-698
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

El-Garem Hassan¹,AbdAllah Mohamed²,Omar Heba¹^ORCID,Cordie Ahmed¹,Abdel Alem Shereen¹^ORCID,Mohey Eldin Elzahry Mohamad A.¹,Ghaith Doaa³,Abou El- Soud Neveen H.²,Kamal Walid⁴,Elsharkawy Aisha¹,Esmat Gamal¹⁵

Affiliation:

1. Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt

2. Medical Research Division, National Research Center, Giza, Egypt

3. Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Giza, Egypt

4. Preventive sector, Ministry of Health, Cairo, Egypt

5. Badr University, Cairo, Egypt

Funder

not funded

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474124.2019.1614441

Reference36 articles.

1. Hepatitis C in the HIV (Human Immunodeficiency Virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The Effect of Coinfection on Survival

2. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics

3. Hepatitis C in Egypt

4. HIV Prevalence among HCV Egyptian Infected Patients and Its Impact on the Result of HCV Treatment

5. HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of HCV treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker of intestinal permeability in HCV/HIV co-infected patients;Egyptian Liver Journal;2023-04-29

2. Effect of HCV treatment with DAAs on serum Intestinal Fatty Acid Binding Protein (I-FABP) as a marker of intestinal permeability in HCV/ HIV co- infected patients;2022-08-03

3. Fibrosis regression following hepatitis C antiviral therapy;World Journal of Hepatology;2022-06-27

4. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience;Expert Review of Anti-infective Therapy;2021-11-25

5. Evaluation of long-term changes of aspartate—platelet ratio index, FIB4, and liver stiffness in chronic hepatitis C patients successfully treated by direct-acting antivirals;Egyptian Liver Journal;2021-08-28